Moody's report highlights impending Medicaid cuts, insurer financial pressures, evolving Medicare Advantage rates, and trends in U.S. healthcare leadership and technology.

Analysis shows a 25% increase in U.S. private insurer prescription drug denials from 2016-2023, driven by rising drug costs and claim automation. Insights into industry impact and reform efforts.